Progyny, Inc. Revenue
Progyny, Inc. (PGNY) reported Revenue of $350.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $350.51M, a 5.30% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $328.50M, a 1.38% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $318.40M, a 6.69% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $313.35M, a 9.32% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.29B, a 10.40% increase from fiscal 2024.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.17B, a 7.22% increase from fiscal 2023.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.09B, a 38.34% increase from fiscal 2022.
- Progyny, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $786.91M, a 57.19% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $350.51M 10-Q · filed 2026-08-07 | $679.01M 10-Q · filed 2026-08-07 | $997.42M derived: sum of 3 quarters · filed 2026-08-07 | $1.31B derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $328.50M 10-Q · filed 2026-05-08 | $646.91M derived: sum of 2 quarters · filed 2026-05-08 | $960.25M derived: sum of 3 quarters · filed 2026-05-08 | $1.29B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $318.40M 10-K · filed 2026-02-27 | $631.75M derived: sum of 2 quarters · filed 2026-02-27 | $964.62M derived: sum of 3 quarters · filed 2026-08-07 | $1.29B 10-K · filed 2026-02-27 |
| 2025-09-30 | $313.35M 10-K · filed 2026-02-27 | $646.22M derived: sum of 2 quarters · filed 2026-08-07 | $970.26M 10-Q · filed 2025-11-07 | $1.27B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $332.87M 10-Q · filed 2026-08-07 | $656.91M 10-Q · filed 2026-08-07 | $955.34M derived: sum of 3 quarters · filed 2026-08-07 | $1.24B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $324.04M 10-Q · filed 2026-05-08 | $622.47M derived: sum of 2 quarters · filed 2026-05-08 | $909.09M derived: sum of 3 quarters · filed 2026-05-08 | $1.21B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $298.43M 10-K · filed 2026-02-27 | $585.06M derived: sum of 2 quarters · filed 2026-02-27 | $889.14M derived: sum of 3 quarters · filed 2026-02-27 | $1.17B 10-K · filed 2026-02-27 |
| 2024-09-30 | $286.63M 10-K · filed 2026-02-27 | $590.71M derived: sum of 2 quarters · filed 2026-02-27 | $868.79M 10-Q · filed 2025-11-07 | $1.14B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $304.09M 10-K · filed 2026-02-27 | $582.16M 10-Q · filed 2025-08-08 | $852.11M derived: sum of 3 quarters · filed 2026-02-27 | $1.13B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $278.08M 10-K · filed 2026-02-27 | $548.02M derived: sum of 2 quarters · filed 2026-02-27 | $828.91M derived: sum of 3 quarters · filed 2026-02-27 | $1.11B derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $269.94M 10-K · filed 2025-03-03 | $550.83M derived: sum of 2 quarters · filed 2025-03-03 | $830.20M derived: sum of 3 quarters · filed 2025-03-03 | $1.09B 10-K · filed 2026-02-27 |
| 2023-09-30 | $280.89M 10-K · filed 2025-03-03 | $560.26M derived: sum of 2 quarters · filed 2025-03-03 | $818.66M derived: sum of 3 quarters · filed 2025-03-03 | $1.03B derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $279.37M 10-K · filed 2025-03-03 | $537.77M derived: sum of 2 quarters · filed 2025-03-03 | $752.09M derived: sum of 3 quarters · filed 2025-03-03 | $957.46M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $258.39M 10-K · filed 2025-03-03 | $472.71M derived: sum of 2 quarters · filed 2025-03-03 | $678.09M derived: sum of 3 quarters · filed 2025-03-03 | $873.09M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $214.32M 10-K · filed 2024-02-29 | $419.69M derived: sum of 2 quarters · filed 2024-02-29 | $614.70M derived: sum of 3 quarters · filed 2024-02-29 | $786.91M 10-K · filed 2025-03-03 |
| 2022-09-30 | $205.37M 10-K · filed 2024-02-29 | $400.38M derived: sum of 2 quarters · filed 2024-02-29 | $572.59M derived: sum of 3 quarters · filed 2024-02-29 | $700.14M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $195.00M 10-K · filed 2024-02-29 | $367.22M derived: sum of 2 quarters · filed 2024-02-29 | $494.77M derived: sum of 3 quarters · filed 2024-02-29 | $617.06M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $172.22M 10-K · filed 2024-02-29 | $299.77M derived: sum of 2 quarters · filed 2024-02-29 | $422.05M derived: sum of 3 quarters · filed 2024-02-29 | $550.71M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $127.55M 10-K · filed 2023-03-01 | $249.84M derived: sum of 2 quarters · filed 2023-03-01 | $378.49M derived: sum of 3 quarters · filed 2023-03-01 | $500.62M 10-K · filed 2024-02-29 |
| 2021-09-30 | $122.28M 10-K · filed 2023-03-01 | $250.94M derived: sum of 2 quarters · filed 2023-03-01 | $373.07M derived: sum of 3 quarters · filed 2023-03-01 | |
| 2021-06-30 | $128.65M 10-K · filed 2023-03-01 | $250.78M derived: sum of 2 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $122.13M 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $344.86M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |